Страна: Ирландия
Язык: английский
Источник: HPRA (Health Products Regulatory Authority)
INDIUM OXINE (IN-111)
GE Healthcare Limited
INDIUM OXINE (IN-111)
%v/v
Radio-Pharm Precursor
Withdrawn
2009-08-01
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Indium [ 111 In] Oxine Solution Indium [ 111 In] Oxine 37MBq/ml Radiopharmaceutical Precursor 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Indium [ 111 In]Oxine complex 37 MBq/vial (No carrier added) (37 MBq/ml) at the activity reference date 111 In disintegrates by electron capture with a half-life of approximately 67 hours (2.8 days) and emits gamma radiation with principal energies of 172 keV (91%) and 246 keV (94%). By internal conversion, X radiations of 23 and 26 keV are also emitted. For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Radiopharmaceutical Precursor. Clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Indium [ 111 In] oxine is used as an ingredient for the _in vitro _radiolabelling of separated blood cells which are subsequently administered intravenously for a variety of investigative purposes using appropriate imaging/counting procedures. Investigative procedures using indium [ 111 In]-labelled blood cells include: _-_ _111_ _In-labelled leucocytes or granulocytes: _Investigation of sites of inflammatory processes and abscesses, complementary with other imaging investigations; for example, localisation of sites of focal infection such as abdominal abscess, confirmation of bone infection after prosthesis, investigation of pyrexia of unknown origin and evaluation of inflammatory conditions not associated with infection such as inflammatory bowel disease. In red marrow bearing regions of the skeleton, osteomyelitis may present as sites of reduced uptake of 111 In-labelled leucocytes. Diffuse or local pulmonary uptake of 111 In-labelled leucocytes should be interpreted with caution, as this can be due to physiological marginal location. _-_ _111_ _In-labelled platelets (thrombocytes)_: Прочитать полный документ